ERBB2 and breast carcinoma: Hence, the objectives of this study were to assess the cost-utility and budget impact of therapy with dual HER2-targeted regimens (trastuzumab and pertuzumab/lapatinib) to single HER2-targeted regimens with trastuzumab for the neoadjuvant treatment of HER2-positive breast cancer in Sri Lanka.